Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sargazi, Saman | - |
dc.contributor.author | Saravani, Ramin | - |
dc.contributor.author | Zavar Reza, Javad | - |
dc.contributor.author | Jaliani, Hossein Zarei | - |
dc.contributor.author | Mirinejad, Shekoufeh | - |
dc.contributor.author | Rezaei, Zohreh | - |
dc.contributor.author | Zarei, Sadegh | - |
dc.date.accessioned | 2020-02-17T13:28:40Z | - |
dc.date.available | 2020-02-17T13:28:40Z | - |
dc.date.issued | 2019-07-08 | - |
dc.identifier.issn | 1611-2156 | - |
dc.identifier.uri | http://hdl.handle.net/2003/38600 | - |
dc.identifier.uri | http://dx.doi.org/10.17877/DE290R-20519 | - |
dc.description.abstract | Cancer therapies using defects in homologous recombination (HR) DNA repair pathway of tumor cells are not yet approved to be applicable in patients with malignancies other than BRCA1/2-mutated tumors. This study was designed to determine the efficacy of combination therapy of a histone deacetyl ase inhibitor, valproic acid (VPA) and a novel PARP inhibitor AZD2461 in both PC-3 (PTEN-mutated) and DU145 (PTEN-unmutated) prostate cancer cell lines. The Trypan blue dye exclusion assay an d the tetrazolium-based colorimetric (MTT) assay were performed to measure the cytotoxicity while combination effects were assessed based on Chou-Talalay's princi- ples. Flow-cytometric assay determined the type of cell deat h. The real-time PCR analysis was used to evaluate the alterations in mRNA levels of HR-related genes while their protein levels were measured using the ELISA method. γ -H2AX levels were determined as a marker of DNA damage. We observed a synergistic relationship between VPA and AZD2461 in all affected fractions of PC-3 cells (CI<0.9), but not in DU145 cells (CI>1.1). Annexin-V staining analysis revealed a significant induction of apoptosis when PC-3 cells were treated with VPA+AZD2461 ( p<0.05 ). Both mRNA and protein levels of Rad51 and Mre11 were significantly decreased in PC-3 cells co-treated with VPA+AZD2461 while enhanced H2AX phosphorylation was found in PC-3 cells after 12 and 24 hours of co-treatment ( p<0.05 ). Our findings established a preclinical rationale for selective targeting of HR repair pathways by a combination of VPA and AZD2461 as a mechanism for reducing the HR pathway sufficiency in PTEN -mutated prostate cancer cells. | en |
dc.language.iso | en | - |
dc.relation.ispartofseries | EXCLI Journal;Vol. 18 2019 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.subject | AZD2461 | en |
dc.subject | Drug combination | en |
dc.subject | Prostate cancer | en |
dc.subject | PTEN | en |
dc.subject | Valproic acid | en |
dc.subject.ddc | 610 | - |
dc.title | Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid | en |
dc.type | Text | - |
dc.type.publicationtype | article | - |
dcterms.accessRights | open access | - |
eldorado.dnb.zdberstkatid | 2132560-1 | - |
eldorado.secondarypublication | true | - |
Appears in Collections: | Original Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Sargazi_Saravani_08072019_proof.pdf | DNB | 786.09 kB | Adobe PDF | View/Open |
This item is protected by original copyright |
This item is licensed under a Creative Commons License